Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Details : The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent gl...
Product Name : ATD-001
Product Type : Other Small Molecule
Upfront Cash : $2.5 million
January 06, 2023
Reset All
